Design and development of solid nanoparticulate dosage forms of telmisartan for bioavailability enhancement by integration of experimental design and principal component analysis

Powder Technology

Volumn 258, Issue , 2014, Pages 331-343

  Patel, Jaydeep ^a   Dhingani, Anjali ^a   Garala, Kevin ^a   Raval, Mihir ^b   Sheth, Navin ^b  

^a Atmiya Institute of Pharmacy   (India)

^b SAURASHTRA UNIVERSITY   (India)

Author keywords

Bioavailability; Nanocrystals; Nanosuspension; Principal component analysis; Quality by design; Telmisartan

Indexed keywords

BIOCHEMISTRY; COMMERCE; DESIGN; DESIGN OF EXPERIMENTS; MILLING (MACHINING); NANOCRYSTALS; OPTIMIZATION; PRINCIPAL COMPONENT ANALYSIS;

BIOAVAILABILITY; BIOAVAILABILITY ENHANCEMENTS; INSTRUMENTAL TECHNIQUES; NANO-SUSPENSIONS; ORAL BIOAVAILABILITIES; POORLY WATER-SOLUBLE DRUGS; QUALITY BY DESIGNS; TELMISARTAN;

DRUG DOSAGE;

NANOCRYSTAL; NANOPARTICLE; NANOSUSPENSION; SARTEL; TELMISARTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; DRUG SOLUBILITY; EXPERIMENTAL DESIGN; FACTORIAL DESIGN; FREEZE DRYING; IN VITRO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PRINCIPAL COMPONENT ANALYSIS; PROCESS OPTIMIZATION; RAT; SINGLE DRUG DOSE; TABLET;

EID: 84896929223     PISSN: 00325910     EISSN: 1873328X     Source Type: Journal    
DOI: 10.1016/j.powtec.2014.03.001     Document Type: Article

References (65)

1. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44:235-249.
2. Wening K., Breitkreutz J. Oral drug delivery in personalized medicine: unmet needs and novel approaches. Int. J. Pharm. 2011, 404:1-9.
3. Gupta H., Bhandari D., Sharma A. Recent trends in oral drug delivery: a review. Recent Pat. Drug Deliv. Formul. 2009, 3:162-173.
4. Ruilope L.M. Telmisartan for the management of patients at high cardiovascular risk. Curr. Med. Red. Opin. 2011, 27:1673-1682.
5. Sweetman S.C. Martindale - The Complete Drug Reference 2005, Pharmaceutical Press, London.
6. Kothawade S.N., Kadam N.R., Aragade P.D., Baheti D.G. Formulation and characterization of telmisatan solid dispersions. Int. J. Pharm. Technol. Res. 2010, 2:341-347.
7. Patel B., Parikh R.H., Swarnakar D. Enhancement of dissolution of telmisartan through the use of solid dispersion technique-surface solid dispersion. J. Pharm. Bioall. Sci. 2012, 4:64-68.
8. Zhang Y., Jiang T., Zhang Q., Wang S. Inclusion of telmisartan in mesocellular foam nanoparticles: drug loading and release property. Eur. J. Pharm. Biopharm. 2010, 76:17-23.
9. Müller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 2001, 47:3-19.
10. Libo W., Jian Z., Wiwik W. Physical and chemical stability of drug nanoparticles. Adv. Drug Deliv. Rev. 2011, 63:456-469.
11. Date A.A., Patravale V.B. Current strategies for engineering drug nanoparticles. Curr. Opin. Colloid Interface Sci. 2004, 9:222-235.
12. Kaul G., Huang J., Chatlapalli R., Ghosh K., Nagi A. Quality-by-design case study: investigation of the role of poloxamer in immediate-release tablets by experimental design and multivariate data analysis. AAPS PharmSciTech 2011, 12:1064-1076.
13. Lionberger R.A., Lee S.L., Lee L., Raw A., Yu L.X. Quality-by-design: concepts for ANDAs. AAPS J. 2008, 10:268-276.
14. Niwa T., Miura S., Danjo K. Universal wet-milling technique to prepare oral nanosuspension focused on discovery and preclinical animal studies - development of particle design method. Int. J. Pharm. 2011, 405:218-227.
15. Balakrishnan P., Lee B.J., Oh D.H., Kim J.O., Hong M.J., Jee J.P., Kim J.A., Yoo B.K., Woo J.S., Yong C.S., Choi H.G. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur. J. Pharm. Biopharm. 2009, 72:539-545.
16. Patel D., Sawant K.K. Self microemulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs. Curr. Drug Deliv. 2009, 6:419-424.
17. Sigfridsson K., Lundgvist A., Strimfors M. Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor-the importance of gastrointestinal pH and solubility for the in vivo exposure. Drug Dev. Ind. Pharm. 2011, 37:1036-1042.
18. Sigfridsson K.S., Nordmark A., Theilig S., Lindahl A. A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. Drug Dev. Ind. Pharm. 2011, 37:185-192.
19. Cerdeira A.M., Mazzoti M., Gander B. Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability. Int. J. Pharm. 2010, 396:210-218.
20. Li W., Yang Y., Tian Y., Xu X., Chen Y., Mu L., Zhang Y., Fang L. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int. J. Pharm. 2011, 408:157-162.
21. Kayaert P., Van den Mooter G. Is the amorphous fraction of a dried nanosuspension caused by milling or by drying? A case study with naproxen and cinnarizine. Eur. J. Pharm. Biopharm. 2012, 81:650-656.
22. Bolton S. Optmization techniques in pharmaceutical statistics: practical and clinical applications 1997, Marcel Dekker, Inc., New York.
23. Singh B., Kumar R., Ahuja N. Optimizing drug delivery systems using systematic "design of experiments". Part I: fundamental aspects. Crit. Rev. Ther. Drug Carrier Syst. 2005, 22:27-105.
24. Ringnér M. What is principal component analysis?. Nat. Biotechnol. 2008, 26:303-304.
25. Rajalahti T., Kvalheim O.M. Multivariate data analysis in pharmaceutics: a tutorial review. Int. J. Pharm. 2011, 417:280-290.
26. Garala K., Patel J., Patel A., Dharamsi A. Enhanced encapsulation of metoprolol tartrate with carbon nanotubes as adsorbent. Appl. Nanosci. 2011, 1:219-230.
27. Ambrus R., Kocbek P., Kristl J., Sibanc R., Rajkó R., Szabó-Révész P. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. Int. J. Pharm. 2009, 381:153-159.
28. Ghosh I., Bose S., Vippagunta R., Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int. J. Pharm. 2011, 409:260-268.
29. Nakarani M., Patel P., Patel J. Cyclosporine nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation. Sciatica Pharm. 2010, 78:345-361.
30. Teeranachaideekul V., Junyaprasert V.B., Souto E.B., Muller R.H. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int. J. Pharm. 2008, 354:227-234.
31. Singh K.K., Srinivasan K.K., Gowthamarajan K., Singare D.S., Prakash D., Gaikwad N.B. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur. J. Pharm. Biopharm. 2011, 78:441-446.
32. Kakran M., Shegokar R., Sahoo N.G., Gohla S., Li L., Müller R.H. Long-term stability of quercetin nanocrystals prepared by different methods. J. Pharm. Pharmacol. 2012, 4:1394-1402.
33. Gao Y., Li Z., Sun M., Guo C., Yu A., Xi Y., Cui J., Lou H., Zhai G. Preparation and characterization of intravenously injectable curcumin nanosuspension. Drug Deliv. 2011, 18:131-142.
34. Costa P., Lobo J.M.S. Modeling and comparison of dissolution profiles. Eur. J. Pharm. 2001, 13:123-133.
35. Bose S., Schenck D., Ghosh I., Hollywood A., Maulit E., Ruegger C. Application of spray granulation for conversion of a nanosuspension into a dry powder form. Eur. J. Pharm. 2012, 47:35-43.
36. Wangi Y., Liu Z., Zhang D., Gao X., Zhang X., Duan C., Jia L., Feng F., Huang Y., Shen Y., Zhang Q. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension. Colloids Surf., B 2011, 83:189-197.
37. Hou C.D., Wang J.X., Le Y., Zou H.K., Zhao H. Preparation of azithromycin nanosuspensions by reactive precipitation method. Drug Dev. Ind. Pharm. 2012, 38:848-854.
38. Sharma P., Zujovic Z.D., Bowmaker G.A., Denny W.A., Garg S. Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies. Int. J. Pharm. 2011, 408:138-151.
39. Salazar J., Heinzerling O., Müller R.H., Möschwitzer J.P. Process optimization of a novel production method for nanosuspensions using design of experiments (DoE). Int. J. Pharm. 2011, 420:395-403.
40. Beirowski J., Inghelbrecht S., Arien A., Gieseler H. Freeze-drying of nanosuspensions, 1: freezing rate versus formulation design as critical factors to preserve the original particle size distribution. J. Pharm. Sci. 2011, 100:1958-1968.
41. Wang P., Luo Q., Miao Y., Ying L., He H., Cai C., Tang X. Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. Drug Dev. Ind. Pharm. 2012, 38:1344-1353.
42. Banker G.S. Tablets. The Theory and Practice of Industrial Pharmacy 1987, 293-345. Varghese Publishing House. 3rd ed. L. Lachman, H.A. Liberman (Eds.).
43. Sahoo N.G., Kakran M., Shaal L.A., Li L., Muller R.H., Pal M., Tan L.P. Preparation and characterization of quercetin nanocrystals. J. Pharm. Sci. 2011, 100:2379-2390.
44. Gahoi S., Jain G.K., Tripathi R., Pandey S.K., Anwar M., Warsi M.H., Singhal M., Khar R.K., Ahmad F.J. Enhanced antimalarial activity of lumefantrine nanopowder prepared by wet-milling DYNO MILL technique. Colloids Surf., B 2012, 95:16-22.
45. Basa S., Muniyappan T., Karatgi P., Prabhu R., Pillai R. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev. Ind. Pharm. 2008, 34:1209-1218.
46. Indian Pharmacopoeia (IP) 2010, The Controller of Publication, New Delhi.
47. Nekkanti V., Pillai R., Venkateshwarlu V., Harisudhan T. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Pharm. Dev. Technol. 2009, 14:290-298.
48. Jonghwi L. Drug nano- and microparticles processed into solid dosage forms: physical properties. J. Pharm. Sci. 2003, 92:2057-2068.
49. Chingunpitak J., Puttipipatkahchorn S., Chavallitshewinkoon-Petmitr P., Tozuka Y., Moribe K., Yamamoto K. Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method. Drug Dev. Ind. Pharm. 2008, 34:314-322.
50. Liu P., Rong X., Laru J., Van Veen B., Kievaara J., Hirvonen J., Laaksonen T., Peltonen L. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int. J. Pharm. 2011, 411:215-222.
51. Ghosh M.N. Fundamentals of Experimental Pharmacology 2008, SK Ghosh & Others, Calcutta, India. 3rd ed.
52. Wu X., Xu J., Huang X., Wen C. Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability. Drug Dev. Ind. Pharm. 2011, 37:15-23.
53. Brahmankar D.M., Jaiswal B.S. Biopharmaceutics and Pharmacokinetics: A treatise 1987, Vallabh Prakashan, New Delhi. 1st ed.
54. Dixit A.R., Rajput S.J., Patel S.G. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech 2010, 11:314-321.
55. Xia D., Quan P., Piao H., Piao H., Sun S., Yin Y., Cui F. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur. J. Pharm. 2010, 40:325-334.
56. Sun M., Si L., Zhai X., Fan Z., Ma Y., Zhang R., Yang X. The influence of co-solvents on the stability and bioavailability of rapamycin formulated in self-microemulsifying drug delivery systems. Drug Dev. Ind. Pharm. 2011, 37:986-994.
57. Dolenc A., Kristl J., Baumgartner S., Planinsek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int. J. Pharm. 2009, 376:204-212.
58. Bhakay A., Merwade M., Bilgili E., Dave R.N. Novel aspects of wet milling for the production of microsuspensions and nanosuspensions of poorly water soluble drugs. Drug Dev. Ind. Pharm. 2011, 37:963-976.
59. Singare D.S., Marella S., Gowthamrajan K., Kulkarni G.T., Vooturia R., Rao P.S. Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int. J. Pharm. 2010, 402:213-220.
60. Van Eerdenbrugh B., Vermant J., Martens J.A., Froyen L., Van Humbeeck J., Augustijns P., Van den Mooter G. A screening study of surface stabilization during the production of drug nanocrystals. J. Pharm. Sci. 2009, 98:2091-2103.
61. Lee J., Choi J.Y., Park C.H. Characteristics of polymers enabling nanocomminution of water-insoluble drugs. Int. J. Pharm. 2008, 355:328-336.
62. Ganta S., Paxton J., Baguley B.C., Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int. J. Pharm. 2009, 367:179-186.
63. Zhang D., Tan T., Gao L., Zhao W., Wang P. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev. Ind. Pharm. 2007, 33:569-575.
64. Muller R.H., Jacobs C. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 2002, 19:189-194.
65. Deng J., Huang L., Liu F. Understanding the structure and stability of paclitaxel nanocrystals. Int. J. Pharm. 2010, 390:242-249.